The Pharmacy Times® Retail Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to retail, community, and independent pharmacists.
April 30th 2025
Biomarker testing transforms non-small cell lung cancer treatment, enhancing outcomes through targeted therapies and next-generation sequencing for better patient care.
New Treatment Available for “Off” Episodes in Patients with Parkinson Disease
October 16th 2019Kyowa Kirin’s istradefylline (Nourianz) is now available in the United States as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) that are experiencing “off” episodes.
Read More
Asenapine Approved as First Transdermal Patch for Treatment of Schizophrenia
October 15th 2019Officials from the FDA have approved Noven Pharmaceuticals, Inc.’s asenapine (Secuado) transdermal system, which is the first-and-only transdermal patch for the treatment of adults with schizophrenia, according to the company.
Read More
Courier Service Delivering Health Care to Pharmacy Customers in Texas
October 10th 2019Prescription medications and other health care items, including vitamins and supplements, eyewear, and natural medicine, such as pharmaceutical-grade CBD oil, is being delivered in the Dallas-Fort Worth (DFW) area with service to homes and offices.
Read More
FDA Approves Brolucizumab for Wet Age-Related Macular Degeneration
October 8th 2019Brolucizumab is the most clinically advanced humanized single-chain antibody fragment. This type of antibody is highly sought after due to their small size, enhanced tissue penetration, rapid clearance from systemic circulation, and drug delivery characteristics.
Read More
FDA Approves Trifarotene Cream for Acne Treatment
October 8th 2019Trifarotene is the only topical retinoid that selectively targets retinoic acid receptor (RAR) gamma, the most common RAR found in the skin. The cream is also the first topical treatment specifically studied and proven to treat both facial (forehead, cheeks, nose, and chin) and truncal (chest, shoulders, and back).
Read More
Treatment for C difficile Shows Promising Potential in First-in-Human Phase 1 Trial
October 6th 2019A first-in-human trial evaluating the safety, pharmacokinetics, and fecal microbiome effects of a novel DNA polIIIC inhibitor demonstrated the antibacterial’s promise as a potential treatment alternative to vancomycin for the treatment of Clostridioides difficile.
Read More
FDA Aims to Improve Oversight of Compounding Pharmacies with Data-Sharing System
October 4th 2019The FDA has awarded a cooperative agreement grant to the National Association of Boards of Pharmacy to develop a 3-year pilot project for a data-sharing system to improve oversight of compounding pharmacies.
Read More